Global real estate investor focused on logistics warehouses
A wave of local and state actions is shaping the data-center boom. New rules aim to curb power use, water consumption and cost pressures, while critics warn of overreach and uneven economic impacts.
Ocado is facing questions over Tim Steiner’s pay and potential succession amid a slide in its share price to below its 2010 flotation level. The board is considering replacements as shareholders voice concerns over pay proportionality and performance.
Prologis has made an all-share approach worth 925p a Segro share, valuing Segro at about 3.6bn. Segro’s board has rejected the bid as “a long way short” of value, arguing the US bid undervalues the business. Shares have rallied on the news, while broader property stocks are buoyed by falling gilt yields and hopes of cheaper financing.
The US and Iran have exchanged fresh strikes this weekend and on Monday, reversing a recent interim ceasefire and re‑opening doubt over control of the Strait of Hormuz. President Donald Trump has declared the ceasefire "over," ordered further strikes and revoked a temporary oil waiver. Oil has jumped into the high $70s–$80s and global markets have fallen.
Mitie has accepted an offer from OCS Group valuing the company at about £3.1 billion, with shareholders set to receive up to 221.6p per share in cash and dividends. The deal, subject to shareholder and court approval, aims to accelerate growth and expand service capabilities. OCS Group would add Mitie’s 84,000-strong workforce and key contracts across government, NHS, transport hubs and airports to a larger UK facilities-management platform.
Segro has accepted Prologis’ best-and-final cash-and-stock offer and extended the put-up-or-shocket deadline to 12 August. The deal values Segro at about £10.32 per share and would create a pan-European warehouse giant focused on AI datacentres and online retail logistics.
GSK has announced a 1.9 billion cost-cutting programme and a shift of more than 1,000 scientists to a new Cambridge R&D campus from Stevenage by 2029, part of broader plans to cut costs and expand late-stage trials.